Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB) (Empowur)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03492281
Recruitment Status : Completed
First Posted : April 10, 2018
Last Update Posted : January 18, 2020
Sponsor:
Information provided by (Responsible Party):
Urovant Sciences GmbH

Tracking Information
First Submitted Date  ICMJE March 21, 2018
First Posted Date  ICMJE April 10, 2018
Last Update Posted Date January 18, 2020
Actual Study Start Date  ICMJE March 26, 2018
Actual Primary Completion Date January 10, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: December 7, 2018)
  • Efficacy; Change from baseline in average number of micturitions per 24 hours [ Time Frame: 12 weeks ]
    Change from baseline (CFB) in average number of micturitions per 24 hours (in all OAB patients)
  • Efficacy; Channge from baseline in average number of urge urinary incontinence episodes per 24 hours [ Time Frame: 12 weeks ]
    Change from baseline in average number of urge urinary incontinence episodes per 24 hours (in OAB Wet patients)
Original Primary Outcome Measures  ICMJE
 (submitted: April 2, 2018)
  • Efficacy; Change from baseline in average number of micturitions per 24 hours [ Time Frame: 12 weeks ]
    Change from baseline (CFB) in average number of micturitions per 24 hours
  • Efficacy; Channge from baseline in average number of urge urinary incontinence episodes per 24 hours [ Time Frame: 12 weeks ]
    Change from baseline in average number of urge urinary incontinence episodes per 24 hours
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: December 7, 2018)
  • CFB at Week 12 in average number of urgency episodes over 24 hours in all OAB patients [ Time Frame: 12 weeks ]
  • Percent of OAB Wet patients with at least a 75% reduction from baseline in UUI episodes per 24 hours at Week 12 [ Time Frame: 12 weeks ]
  • Percent of OAB Wet patients with a 100% reduction from baseline in UUI episodes per 24 hours at Week 12 [ Time Frame: 12 weeks ]
  • Percent of all OAB patients with at least a 50% reduction from baseline in urgency episodes per 24 hours at Week 12 [ Time Frame: 12 weeks ]
  • CFB at Week 12 in average number of total incontinence episodes over 24 hours in OAB Wet patients [ Time Frame: 12 weeks ]
  • CFB at Week 12 in Coping Score from the Overactive Bladder Questionnaire Long Form (OAB-q LF) in all OAB patients [ Time Frame: 12 weeks ]
  • CFB at Week 12 in average volume voided per micturition in all OAB patients [ Time Frame: 12 weeks ]
  • CFB at Week 12 in Health-related Quality of Life (HRQL) Total Score from the OAB-q LF in all OAB patients [ Time Frame: 12 weeks ]
  • CFB at Week 12 in Symptom Bother Score from the OAB-q-LF in all OAB patients [ Time Frame: 12 weeks ]
  • Percent of all OAB patients with average number of micturitions < 8 per 24 hours at Week 12 [ Time Frame: 12 weeks ]
  • Percent of OAB Wet patients with at least a 50% reduction from baseline in total incontinence episodes per 24 hours at Week 12 [ Time Frame: 12 weeks ]
  • CFB at Week 12 in overall bladder symptoms based on Patient Global Impression of Severity (PGI-Severity) in all OAB patients [ Time Frame: 12 weeks ]
  • CFB at Week 12 in overall control over bladder symptoms based on Patient Global Impression of Control (PGI-Control) in all OAB patients [ Time Frame: 12 weeks ]
Original Secondary Outcome Measures  ICMJE
 (submitted: April 2, 2018)
  • CFB at Week 12 in average number of total incontinence episodes in OAB Wet patients [ Time Frame: 12 weeks ]
  • CFB at Week 12 in average number of urgency episodes [ Time Frame: 12 weeks ]
  • CFB at Week 12 in average volume voided per micturition [ Time Frame: 12 weeks ]
  • CFB at Week 12 in Coping Score from the Overactive Bladder Questionnaire Long Form [ Time Frame: 12 weeks ]
  • CFB at Week 12 in Health-related Quality of Life Total Score from the OAB-q LF [ Time Frame: 12 weeks ]
  • CFB at Week 12 in Symptom Bother Score from the OAB-q-LF [ Time Frame: 12 weeks ]
  • CFB at Week 12 on Patient Global Impression of Control [ Time Frame: 12 weeks ]
  • CFB at Week 12 on Patient Global Impression of Severity [ Time Frame: 12 weeks ]
  • CFB at Week 4 in average number of daily micturitions in all OAB patients [ Time Frame: 4 weeks ]
  • CFB at Week 4 in average number of daily UUI episodes in OAB Wet patients [ Time Frame: 4 weeks ]
  • CFB to Week 2 in average number of micturitions [ Time Frame: 2 weeks ]
  • CFB to Week 2 in average number of UUI episodes in OAB Wet patients [ Time Frame: 2 weeks ]
  • Percent of all OAB patients with a 50% reduction from baseline in urgency episodes at Week 12 [ Time Frame: 12 weeks ]
  • Percent of all OAB patients with average number of micturitions < 8 at Week 12 [ Time Frame: 12 weeks ]
  • Percent of OAB Wet patients with a 50% reduction from baseline in total incontinence at Week 12 [ Time Frame: 12 weeks ]
  • Percent of OAB Wet patients with a 75% reduction from baseline in UUI episodes at Week 12 [ Time Frame: 12 weeks ]
  • Percent of OAB Wet patients with zero UUI episodes at Week 12 [ Time Frame: 12 weeks ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study to Examine the Safety and Efficacy of a New Drug in Patients With Symptoms of Overactive Bladder (OAB)
Official Title  ICMJE An International Phase 3, Randomized, Double-Blind, Placebo- and Active (Tolterodine)-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Vibegron in Patients With Symptoms of Overactive Bladder
Brief Summary This study is designed to evaluate the safety, tolerability, and efficacy of vibegron administered once daily in patients with OAB.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Overactive Bladder
Intervention  ICMJE
  • Drug: vibegron
    single daily oral dose of vibegron 75mg for 12 weeks
    Other Names:
    • RVT-901
    • MK4618
    • KRP114V
    • URO-901
  • Drug: Vibegron placebo
    placebo to match vibegron (experimental drug)
  • Drug: Tolterodine Tartrate ER
    active comparator
    Other Name: Mariosea XL
  • Drug: Tolterodine placebo
    placebo to match tolterodine (active comparator)
Study Arms  ICMJE
  • Experimental: Vibegron + Placebo to match Tolterodine
    Interventions:
    • Drug: vibegron
    • Drug: Tolterodine placebo
  • Placebo Comparator: Placebo to match vibegron + Placebo to match Tolterodine
    Interventions:
    • Drug: Vibegron placebo
    • Drug: Tolterodine placebo
  • Active Comparator: Tolterodine + Placebo to match vibegron
    Interventions:
    • Drug: Vibegron placebo
    • Drug: Tolterodine Tartrate ER
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: November 8, 2018)
1530
Original Estimated Enrollment  ICMJE
 (submitted: April 2, 2018)
1400
Actual Study Completion Date  ICMJE February 4, 2019
Actual Primary Completion Date January 10, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Has a history of OAB for at least 3 months prior to the Screening Visit.
  2. Meets either the OAB Wet or OAB Dry criteria.

Exclusion Criteria:

Urology Medical History

  1. Patient had an average total daily urine volume > 3000 mL in the past 6 months or during the 14-day Run-in Period.
  2. Has lower urinary tract pathology that could, in the opinion of the Investigator, be responsible for urgency, frequency, or incontinence.
  3. Has a history of surgery to correct stress urinary incontinence, pelvic organ prolapse, or procedural treatments for BPH within 6 months of Screening.
  4. Has current history or evidence of Stage 2 or greater pelvic organ prolapse (prolapse extends beyond the hymenal ring).
  5. Patient is currently using a pessary for the treatment of pelvic organ prolapse.
  6. Has a known history of elevated post-void residual volume defined as greater than 150 mL.
  7. Has undergone bladder training or electrostimulation within 28 days prior to Screening or plans to initiate either during the study.
  8. Has an active or recurrent (> 3 episodes per year) urinary tract infection by clinical symptoms or pre-defined laboratory criteria.
  9. Has a requirement for an indwelling catheter or intermittent catheterization.
  10. Has received an intradetrusor injection of botulinum toxin within 9 months prior to Screening.
  11. Has uncontrolled hyperglycemia (defined as fasting blood glucose > 150 mg/dL or 8.33 mmol/L and/or non-fasting blood glucose > 200 mg/dL or 11.1 mmol/L) or, if in the opinion of the Investigator, is uncontrolled.
  12. Has evidence of diabetes insipidus.
  13. Is pregnant, breast-feeding, or is planning to conceive within the projected duration of the study.
  14. Has a concurrent malignancy or history of any malignancy within 5 years prior to signing informed consent, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
  15. Has uncontrolled hypertension (systolic blood pressure of ≥ 180 mmHg and/or diastolic blood pressure of ≥ 100 mmHg) or has a resting heart rate (by pulse) > 100 beats per minute.
  16. Has narrow angle glaucoma (primary open angle glaucoma is not excluded).
  17. Has a history of cerebral vascular accident, transient ischemic attack, unstable angina, myocardial infarction, coronary artery interventions (e.g., coronary artery bypass grafting or percutaneous coronary interventions [e.g., angioplasty, stent insertion]), or neurovascular interventions (e.g., carotid artery stenting) within 6 months prior to the Screening Visit. Has a known history of liver disease.
  18. Has a history of injury, surgery, or neurodegenerative diseases (e.g., multiple sclerosis, Parkinson's) that could affect the lower urinary tract or its nerve supply.
  19. Has hematuria, including microscopic hematuria according to pre-defined criteria.
  20. Has clinically significant electrocardiogram (ECG) abnormality.
  21. Has alanine aminotransferase or aspartate aminotransferase > 2.0 times the upper limit of normal (ULN), or bilirubin (total bilirubin) > 1.5 x ULN (or > 2.0 x ULN if secondary to Gilbert syndrome or pattern consistent with Gilbert syndrome).
  22. Has an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2.
  23. Has an allergy, intolerance, or a history of a significant clinical or laboratory adverse experience associated with any of the active or inactive components of the vibegron formulation or tolterodine formulation.
  24. Is currently participating or has participated in a study with an investigational compound or device within 28 days prior to signing informed consent, or has participated in any previous study with vibegron.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   Hungary,   Latvia,   Lithuania,   Poland,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03492281
Other Study ID Numbers  ICMJE RVT-901-3003
2017-003293-14 ( EudraCT Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: No
Responsible Party Urovant Sciences GmbH
Study Sponsor  ICMJE Urovant Sciences GmbH
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS Account Urovant Sciences GmbH
Verification Date January 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP